Literature DB >> 27351583

Hepatic fat quantification using the two-point Dixon method and fat color maps based on non-alcoholic fatty liver disease activity score.

Tatsuya Hayashi1,2,3,4, Satoshi Saitoh2,5,6, Junji Takahashi1,2, Yoshinori Tsuji1,2, Kenji Ikeda2,5, Masahiro Kobayashi2,5, Yusuke Kawamura2,5, Takeshi Fujii2,7, Masafumi Inoue8, Tosiaki Miyati3, Hiromitsu Kumada2,5.   

Abstract

AIM: The two-point Dixon method for magnetic resonance imaging (MRI) is commonly used to non-invasively measure fat deposition in the liver. The aim of the present study was to assess the usefulness of MRI-fat fraction (MRI-FF) using the two-point Dixon method based on the non-alcoholic fatty liver disease activity score.
METHODS: This retrospective study included 106 patients who underwent liver MRI and MR spectroscopy, and 201 patients who underwent liver MRI and histological assessment. The relationship between MRI-FF and MR spectroscopy-fat fraction was used to estimate the corrected MRI-FF for hepatic multi-peaks of fat. Then, a color FF map was generated with the corrected MRI-FF based on the non-alcoholic fatty liver disease activity score. We defined FF variability as the standard deviation of FF in regions of interest. Uniformity of hepatic fat was visually graded on a three-point scale using both gray-scale and color FF maps. Confounding effects of histology (iron, inflammation and fibrosis) on corrected MRI-FF were assessed by multiple linear regression.
RESULTS: The linear correlations between MRI-FF and MR spectroscopy-fat fraction, and between corrected MRI-FF and histological steatosis were strong (R2  = 0.90 and R2  = 0.88, respectively). Liver fat variability significantly increased with visual fat uniformity grade using both of the maps (ρ = 0.67-0.69, both P < 0.001). Hepatic iron, inflammation and fibrosis had no significant confounding effects on the corrected MRI-FF (all P > 0.05).
CONCLUSIONS: The two-point Dixon method and the gray-scale or color FF maps based on the non-alcoholic fatty liver disease activity score were useful for fat quantification in the liver of patients without severe iron deposition.
© 2016 The Japan Society of Hepatology.

Entities:  

Keywords:  fatty liver; magnetic resonance imaging; non-alcoholic fatty liver disease; non-alcoholic steatohepatitis

Year:  2016        PMID: 27351583     DOI: 10.1111/hepr.12767

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  10 in total

1.  Evaluation of six-point modified dixon and magnetic resonance spectroscopy for fat quantification: a fat-water-iron phantom study.

Authors:  Kei Fukuzawa; Tatsuya Hayashi; Junji Takahashi; Chiharu Yoshihara; Masakatsu Tano; Jun'ichi Kotoku; Satoshi Saitoh
Journal:  Radiol Phys Technol       Date:  2017-08-02

2.  Prediction of nonalcoholic fatty liver disease (NAFLD) activity score (NAS) with multiparametric hepatic magnetic resonance imaging and elastography.

Authors:  Ziying Yin; Matthew C Murphy; Jiahui Li; Kevin J Glaser; Amy S Mauer; Taofic Mounajjed; Terry M Therneau; Heshan Liu; Harmeet Malhi; Armando Manduca; Richard L Ehman; Meng Yin
Journal:  Eur Radiol       Date:  2019-03-18       Impact factor: 5.315

3.  Multiparametric magnetic resonance imaging/magnetic resonance elastography assesses progression and regression of steatosis, inflammation, and fibrosis in alcohol-associated liver disease.

Authors:  Jingbiao Chen; Rosa Martin-Mateos; Jiahui Li; Ziying Yin; Jie Chen; Xin Lu; Kevin J Glaser; Taofic Mounajjed; Hiroaki Yashiro; Jenifer Siegelman; Christopher T Winkelmann; Jin Wang; Richard L Ehman; Vijay H Shah; Meng Yin
Journal:  Alcohol Clin Exp Res       Date:  2021-09-05       Impact factor: 3.928

4.  Quantification of Liver Fat by MRI-PDFF Imaging in Patients with Suspected Non-alcoholic Fatty Liver Disease and Its Correlation with Metabolic Syndrome, Liver Function Test and Ultrasonography.

Authors:  Gajanan A Rodge; Mahesh K Goenka; Usha Goenka; Shivaraj Afzalpurkar; Bhavik B Shah
Journal:  J Clin Exp Hepatol       Date:  2020-12-01

5.  Influence of Gd-EOB-DTPA on proton density fat fraction using the six-echo Dixon method in 3 Tesla magnetic resonance imaging.

Authors:  Tatsuya Hayashi; Kei Fukuzawa; Hiroshi Kondo; Hiroshi Onodera; Shuji Toyotaka; Rie Tojo; Shimpei Yano; Masakatsu Tano; Tosiaki Miyati; Jun'ichi Kotoku; Takahide Okamoto; Keiko Toyoda; Hiroshi Oba
Journal:  Radiol Phys Technol       Date:  2017-09-11

Review 6.  Noninvasive Quantitative Detection Methods of Liver Fat Content in Nonalcoholic Fatty Liver Disease.

Authors:  Shujing Lv; Sushan Jiang; Shousheng Liu; Quanjiang Dong; Yongning Xin; Shiying Xuan
Journal:  J Clin Transl Hepatol       Date:  2018-06-22

7.  Effect of Sodium Glucose Co-Transporter 2 Inhibitors on Liver Fat Mass and Body Composition in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus.

Authors:  Yoshitaka Arase; Koichi Shiraishi; Kazuya Anzai; Hirohiko Sato; Erika Teramura; Kota Tsuruya; Shunji Hirose; Ryuzo Deguchi; Masao Toyoda; Tetsuya Mine; Tatehiro Kagawa
Journal:  Clin Drug Investig       Date:  2019-07       Impact factor: 2.859

8.  Rhus chinensis Mill. Fruits Ameliorate Hepatic Glycolipid Metabolism Disorder in Rats Induced by High Fat/High Sugar Diet.

Authors:  Zihuan Wu; Qingqing Ma; Shengbao Cai; Yilin Sun; Yuanyue Zhang; Junjie Yi
Journal:  Nutrients       Date:  2021-12-15       Impact factor: 5.717

9.  Evaluation of a Whole-Liver Dixon-Based MRI Approach for Quantification of Liver Fat in Patients with Type 2 Diabetes Treated with Two Isocaloric Different Diets.

Authors:  Valentina Brancato; Giuseppe Della Pepa; Lutgarda Bozzetto; Marilena Vitale; Giovanni Annuzzi; Luca Basso; Carlo Cavaliere; Marco Salvatore; Angela Albarosa Rivellese; Serena Monti
Journal:  Diagnostics (Basel)       Date:  2022-02-16

10.  Effects of Different Scan Projections on the Quantitative Ultrasound-Based Evaluation of Hepatic Steatosis.

Authors:  Laura De Rosa; Antonio Salvati; Ferruccio Bonino; Maurizia Rossana Brunetto; Francesco Faita
Journal:  Healthcare (Basel)       Date:  2022-02-14
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.